JCO:输精管切除术与前列腺癌有关?

2014-07-24 何Jason 医学专业新闻

在线发表于《临床肿瘤学杂志》(JCO)的一项队列研究显示,对于接受了输精管切除术的男性人群,前列腺癌风险将出现增加。该研究共纳入超过50,000个样本。总体而言,输精管切除术与前列腺癌风险增加10%有关,与高度恶性和致死性前列腺癌风险增加20%有关。常规接受PSA筛查的男性群体,该风险甚至增加50%。研究的主要作者,来自哈佛大学公共卫生学院的Lorelei A. Mucci, ScD强调,前列腺癌

在线发表于《临床肿瘤学杂志》(JCO)的一项队列研究显示,对于接受了输精管切除术的男性人群,前列腺癌风险将出现增加。该研究共纳入超过50,000个样本。

总体而言,输精管切除术与前列腺癌风险增加10%有关,与高度恶性和致死性前列腺癌风险增加20%有关。常规接受PSA筛查的男性群体,该风险甚至增加50%。

研究的主要作者,来自哈佛大学公共卫生学院的Lorelei A. Mucci, ScD强调,前列腺癌风险的增加是“较小的”。他说:“随访24年间,致死性前列腺癌的累计发病率增加了1.6%。因此,医生在决定进行输精管切除术之前,应充分权衡利弊。”



来自杜克大学的泌尿科医生Stephen Freedland, MD,此前曾进行前列腺癌相关生活方式风险因子的研究。他认为,医生在决定施行输精管切除术之前应充分告知风险,但关于前列腺癌的风险增加,目前仍无法得出最终结论。

Stephen说:“我们对于接受相关手术的患者,应进行严密的监测。但这项研究并不足以改变我们的治疗模式。”

关于输精管切除术与前列腺癌之间的联系,目前仍存在很大争议。

原始出处:

Siddiqui MM1, Wilson KM1, Epstein MM1, Rider JR1, Martin NE1, Stampfer MJ1, Giovannucci EL1, Mucci LA2.Vasectomy and Risk of Aggressive Prostate Cancer: A 24-Year Follow-Up Study.J Clin Oncol. 2014 Jul 7. pii: JCO.2013.54.8446. [Epub ahead of print]


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1891135, encodeId=474e189113558, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 05 19:09:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735318, encodeId=b2bd1e35318a6, content=<a href='/topic/show?id=aacf9381e60' target=_blank style='color:#2F92EE;'>#输精管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93817, encryptionId=aacf9381e60, topicName=输精管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0e233890381, createdName=zhenjiu134, createdTime=Wed Jan 21 09:09:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876679, encodeId=a68e18e66796f, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Apr 28 14:09:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981656, encodeId=d7f41981656d0, content=<a href='/topic/show?id=8d5e9381960' target=_blank style='color:#2F92EE;'>#输精管切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93819, encryptionId=8d5e9381960, topicName=输精管切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Mon Apr 06 19:09:00 CST 2015, time=2015-04-06, status=1, ipAttribution=)]
    2014-08-05 zhaojie88
  2. [GetPortalCommentsPageByObjectIdResponse(id=1891135, encodeId=474e189113558, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 05 19:09:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735318, encodeId=b2bd1e35318a6, content=<a href='/topic/show?id=aacf9381e60' target=_blank style='color:#2F92EE;'>#输精管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93817, encryptionId=aacf9381e60, topicName=输精管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0e233890381, createdName=zhenjiu134, createdTime=Wed Jan 21 09:09:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876679, encodeId=a68e18e66796f, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Apr 28 14:09:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981656, encodeId=d7f41981656d0, content=<a href='/topic/show?id=8d5e9381960' target=_blank style='color:#2F92EE;'>#输精管切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93819, encryptionId=8d5e9381960, topicName=输精管切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Mon Apr 06 19:09:00 CST 2015, time=2015-04-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1891135, encodeId=474e189113558, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 05 19:09:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735318, encodeId=b2bd1e35318a6, content=<a href='/topic/show?id=aacf9381e60' target=_blank style='color:#2F92EE;'>#输精管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93817, encryptionId=aacf9381e60, topicName=输精管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0e233890381, createdName=zhenjiu134, createdTime=Wed Jan 21 09:09:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876679, encodeId=a68e18e66796f, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Apr 28 14:09:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981656, encodeId=d7f41981656d0, content=<a href='/topic/show?id=8d5e9381960' target=_blank style='color:#2F92EE;'>#输精管切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93819, encryptionId=8d5e9381960, topicName=输精管切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Mon Apr 06 19:09:00 CST 2015, time=2015-04-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1891135, encodeId=474e189113558, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Aug 05 19:09:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735318, encodeId=b2bd1e35318a6, content=<a href='/topic/show?id=aacf9381e60' target=_blank style='color:#2F92EE;'>#输精管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93817, encryptionId=aacf9381e60, topicName=输精管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0e233890381, createdName=zhenjiu134, createdTime=Wed Jan 21 09:09:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876679, encodeId=a68e18e66796f, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Apr 28 14:09:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981656, encodeId=d7f41981656d0, content=<a href='/topic/show?id=8d5e9381960' target=_blank style='color:#2F92EE;'>#输精管切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93819, encryptionId=8d5e9381960, topicName=输精管切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Mon Apr 06 19:09:00 CST 2015, time=2015-04-06, status=1, ipAttribution=)]

相关资讯

ASCO 2014:ADT+多西他赛延长转移性前列腺癌总生存期(OS)

2014年美国临床肿瘤学会年会已于当地时间5月30日-6月3日在芝加哥成功举行。会议期间公布了一些非常重要的临床试验的结果,其中“Plenary Session”的四项研究最受关注和期待。下面和大家分享其中一项来自美国东部肿瘤协作组(ECOG)的III期随机试验:激素化疗和激素治疗对激素敏感的、初诊转移性前列腺癌患者的总生存期的影响。 多西他赛可以延长去势治疗后发生进展的转移性前列腺癌患者的总生

ASCO 2014:复发PSA患者即刻ADT 无必要

《期刊观察》(Journal Watch)5月16日新闻。 美国临床肿瘤学会(ASCO)2014年年会上发布的一项观察性研究显示,具有前列腺特异性抗原(PSA)的男性患者,接受前列腺癌治疗后复发时,即刻雄激素阻断疗法(ADT)相较于延迟ADT,并不会让患者受益。 该研究资料来源于国家癌症档案库,研究者抽取了约2000名伴有PSA复发但无癌症复发其他迹象的男性患者,他们接受即刻或延迟ADT治疗至

PLoS ONE:前列腺癌转移的关键信号FOXO4/RUNX2被揭示

2014年7月15日 讯 /生物谷BIOON/ --在许多致死性癌症患者中,超过90%的患者死亡都是因为癌细胞的转移,寻找干扰癌细胞转移的关键路径对于开发新型疗法来抑制肿瘤扩散非常关键;近日,刊登在国际杂志PLoS ONE上的一篇研究论文中,来自帕克癌症研究所(Roswell Park Cancer Institute)的研究人员通过研究鉴别出了一种癌症转移的新型抑制子,这或许为开发治疗前列腺

Lancet Oncol:剂量渐增放疗是否能提高前列腺癌的存活率?

背景资料这项试验的目的是在局部前列腺癌患者中,比较剂量渐增适形放疗与对照剂量适形放疗。 5 年随访后的初步结果显示,剂量渐增适形放疗可提高生化无进展存活率。 基于样本大小计算,我们计划在发生 190 例死亡时进行整体存活率分析;在中值随访期 10 年后,此目标现已达到。方法    RT01 是一项 3 期、开放标签、国际、随机分配对照试验,招募患有经组织学确

CA Cancer J Clin:新前列腺癌幸存者指南

6月10日,美国癌症学会(ACS)发布最新的前列腺癌幸存者生存指南,该指南发表在CA:ACancerJournalforClinicians在线版上。 美国前列腺癌幸存者的人数达将近280万,占全部癌症幸存者的五分之一、超过男性癌症幸存者的十分之四。鉴于前列腺癌治疗后患者的长期生存日渐普遍,要提高该类癌症幸存者的护理情况对其进行明确的特征性描述(积极治疗后的护理期)和满足其独特的需求就具有重要作

武田终止orteronel在日本、美国、欧盟的前列腺癌临床项目

武田(Takeda)6月19日宣布,已自愿决定终止orteronel(TAK-700)用于前列腺癌治疗的临床开发项目。该决定基于在转移性去势抵抗前列腺癌(mCRPC)患者中开展的2个III期临床研究的结果。研究发现,尽管orteronel+泼尼松(prednisone)能够延长患者的无进展生存期(PFS),但并不能延长患者的总生存期(OS)。经过对实验数据的慎重考虑,同时考虑到现有其他疗法的可用性